Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CPT1A | P50416 | 19/20 | 0.62 |
| ▸ | CPT1B | Q92523 | 17/20 | 0.62 |
| ▸ | CPT2 | P23786 | 13/20 | 0.62 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30015351 | 0.86 | CPT1A (0.77) | CPT1ACPT1BCPT2 | |
| SCHEMBL2897793 | 0.86 | CPT1A (0.82) | CPT1ACPT1BCPT2KMT2A | |
| SCHEMBL13571613 | 0.80 | CPT1A (0.58) | CPT1ACPT1BCPT2 | |
| SCHEMBL2901204 | 0.80 | CPT1A (0.82) | CPT1ACPT1BCPT2KMT2A | |
| SCHEMBL4794685 | 0.79 | CPT1A (0.60) | CPT1ACPT1BCPT2KMT2A | |
| SCHEMBL4793974 | 0.78 | CPT1A (0.62) | CPT1ACPT1BCPT2 | |
| SCHEMBL2904385 | 0.78 | CPT1A (0.73) | CPT1ACPT1BCPT2 | |
| SCHEMBL3580255 | 0.77 | CPT1A (1.00) | CPT1ACPT1BCPT2 | |
| SCHEMBL30014606 | 0.77 | CPT1A (1.00) | CPT1ACPT1BCPT2 | |
| SCHEMBL2898348 | 0.76 | CPT1A (0.64) | CPT1ACPT1BCPT2KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1926711-A1 | NOVEL HETEROBICYCLIC DERIVATIVES USEFUL AS INHIBITORS OF LIVER CARNITINE PALMITOYL TRANSFERASE | F.HOFFMANN-LA ROCHE AG (CH) | 2008-06-04 | — | — | EP | disclosed |
| WO-2007031429-A1 | NOVEL HETEROBICYCLIC DERIVATIVES USEFUL AS INHIBITORS OF LIVER CARNITINE PALMITOYL TRANSFERASE | F. HOFFMANN-LA ROCHE AG (CH) | 2007-03-22 | — | — | WO | disclosed |